# Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

> **NCT01581203** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 748 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** Asunaprevir (ASV)
- **DRUG:** Daclatasvir (DCV)
- **DRUG:** Pegylated-interferon alfa 2a (PegIFN)
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT01581203
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-10
- **Final completion:** 2014-09
- **Target enrollment:** 748 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01581203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01581203, "Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01581203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*